Literature DB >> 1672825

Biochemical analysis of the ligand for the neu oncogenic receptor.

Y Yarden1, E Peles.   

Abstract

The neu protooncogene (also called HER2 and c-erbB2) encodes a cell-surface tyrosine kinase structurally related to the receptor for the epidermal growth factor (EGF). We have previously reported that a candidate ligand for the neu receptor is secreted by ras-transformed fibroblasts. Biochemical analyses of the neu stimulatory activity indicate that the ligand is a 35-kDa glycoprotein that is heat stable but sensitive to reduction. The factor is precipitable by either high salt concentrations or acidic alcohol. Partial purification of the molecule by selective precipitation, heparin-agarose chromatography, and gel filtration in dilute acid resulted in an active ligand, which is capable of stimulating the protooncogenic receptor but is ineffective on the oncogenic neu protein, which is constitutively active. The purified fraction, however, retained the ability to stimulate also the related receptor for EGF, suggesting that these two receptors are functionally coupled through a bidirectional mechanism. Alternatively, the presumed ligand interacts simultaneously with both receptors. The presented biochemical characteristics of the factor are expected to enable a completely purified factor with which to explore these possibilities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672825     DOI: 10.1021/bi00228a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  p185neu is expressed in yolk sac during rat postimplantation development.

Authors:  V Knezevic; R Spaventi; L Poljak; N Slade; A Svajger; K Pavelic
Journal:  J Anat       Date:  1994-08       Impact factor: 2.610

2.  Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.

Authors:  U Srinivas; E Tagliabue; M Campiglio; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

3.  Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.

Authors:  D B Ring; S T Hsieh-Ma; T Shi; J Reeder
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

Authors:  I Stancovski; E Hurwitz; O Leitner; A Ullrich; Y Yarden; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

5.  Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.

Authors:  A Orr-Urtreger; L Trakhtenbrot; R Ben-Levy; D Wen; G Rechavi; P Lonai; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

6.  Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

Authors:  R Lupu; R Colomer; B Kannan; M E Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

7.  Impairment of ubiquitylation by mutation in Drosophila E1 promotes both cell-autonomous and non-cell-autonomous Ras-ERK activation in vivo.

Authors:  Hua Yan; Mei-Ling Chin; Elizabeth A Horvath; Elizabeth A Kane; Cathie M Pfleger
Journal:  J Cell Sci       Date:  2009-04-14       Impact factor: 5.285

8.  Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.

Authors:  E Peles; R B Levy; E Or; A Ullrich; Y Yarden
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

9.  Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.

Authors:  Manijeh Mahdavi; Mehrnaz Keyhanfar; Abbas Jafarian; Hassan Mohabatkar; Mohammad Rabbani
Journal:  Tumour Biol       Date:  2014-08-21

10.  Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.

Authors:  E Peles; R Ben-Levy; E Tzahar; N Liu; D Wen; Y Yarden
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.